Carey, 2023 - Google Patents
Chimeric Antigen Receptor T-Cell ImmunotherapyCarey, 2023
View PDF- Document ID
- 5593175604583216739
- Author
- Carey H
- Publication year
- Publication venue
- Microreviews in Cell and Molecular Biology
External Links
Snippet
Abstract Chimeric Antigen Receptor T-Cell therapy is a definitive breakthrough in cancer treatment–it has changed the way certain cancers are managed, as a whole. By using genetically engineered T-cells to fight diseased cells, the body can fight back against …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakamura et al. | Targeting cancer‐related inflammation in the era of immunotherapy | |
| US9132281B2 (en) | Focused radiation for augmenting immune-based therapies against neoplasms | |
| JP2020183413A (en) | TEC family kinase inhibitor adjuvant therapy | |
| Haikerwal et al. | Building immunity to cancer with radiation therapy | |
| CN109069539A (en) | Combined immunization therapy use for cancer treatment and cell factor control therapy | |
| US20240148880A1 (en) | Rejuvenation of car t cell | |
| US20220111069A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
| JP2020528744A (en) | Methods and Compositions for Chimeric Antigen Receptors Targeting Cancer Cells | |
| CN107073107A (en) | Use the cancer treatment method of the combination of antagonist and radiotherapy for PD 1 and PD L1 | |
| Thamm | Canine cancer: strategies in experimental therapeutics | |
| CN107920500A (en) | Derive the matched humanization NSG mouse models of non-HLA of xenograft with patient | |
| CA3128202A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| Darvishi et al. | Recent progress in cancer immunotherapy: Overview of current status and challenges | |
| JP2018526453A (en) | Genetically engineered drug resistant T cells and methods of use thereof | |
| Maroto-Martín et al. | Ps1209 Nkg2d and bcma-car Nk cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant cars | |
| KR102578682B1 (en) | IL8 BLOKING EMT PATHWAY AND OVERCOMING CANCER STEM CELLS | |
| Grzybowski et al. | Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors | |
| Carey | Chimeric Antigen Receptor T-Cell Immunotherapy | |
| Thangaraj et al. | Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model | |
| JP2021502416A5 (en) | ||
| EP3311840B1 (en) | Treatment-resistance reducing agent for treatment-resistant cancer | |
| CN110177552A (en) | For adjusting the composition of PD-1 signal transduction | |
| Hu | Overcome the impairment of NK cells for icon and antibody immunotherapy of cancer | |
| KR20150136818A (en) | Composition for treating hepatic cancer comprising mesenchymal stem cell transfected with IL-12 expressing vector and the treatment methods using the same | |
| Sadeghi et al. | Combination of NK cell immunotherapy with chemotherapy and radiation enhances NK cell therapy and provides improved prognosis in cancer patients and in humanized BLT mouse model system |